imiquimod

(redirected from Zyclara)
Also found in: Dictionary.
Related to Zyclara: Imiquimod

imiquimod

 [im″ĭ-kwim´od]
a biologic response modifier used topically in the treatment of venereal warts of the external genitalia and perianal region.

i·mi·qui·mod

(im'i-kwī'mod),
An immune response modifier used on the skin in the treatment of external genital and perianal warts.
References in periodicals archive ?
The total agreement Meda will cease paying royalties on sales of Acnatac, Aldara and Zyclara to Valeant.
Zyclara (imiquimod 3.75%) has been tested in seven clinical trials in more than 1,400 patients.
Meda acquired the exclusive European rights to Zyclara, a new formulation of imiquimod, from US-based Graceway Pharmaceuticals LLC in May 2010.
In conjunction with the agreement related to Actavis' generic version of Zyclara, it may launch its generic product on 1 January 2019, or earlier under certain circumstances.
Zyclara is a prescription medicine for skin use only to treat actinic keratosis on the full face or balding scalp in adults with a normal immune function.
M2 EQUITYBITES-August 27, 2012-Meda announces approval of Zyclara in EU(C)2012 M2 COMMUNICATIONS http://www.m2.com
Speciality pharmaceutical company Meda AB (STO:MEDAA.ST) announced today that the European Commission (EC) has granted marketing authorisation for Zyclara in the European Union.
M2 PHARMA-August 27, 2012-Meda announces approval of Zyclara in EU(C)2012 M2 COMMUNICATIONS
M2 PHARMA-July 19, 2011-FDA okays Zyclara Cream 2.5% for actinic keratoses treatment(C)2011 M2 COMMUNICATIONS
19 July 2011 - US-based Graceway Pharmaceuticals LLC announced yesterday that the US Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK).
M2 EQUITYBITES-June 23, 2011-MEDA files marketing authorisation for Zyclara in Europe(C)2011 M2 COMMUNICATIONS http://www.m2.com
29 March 2010 - US Graceway Pharmaceuticals LLC said on Friday that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK).